Shattuck Labs (STTK) Competitors $1.37 +0.08 (+6.20%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.39 +0.02 (+1.46%) As of 02/21/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends STTK vs. CTNM, VIRI, ZYBT, DRUG, MOLN, OCGN, INMB, GNFT, FULC, and NLTXShould you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Contineum Therapeutics (CTNM), Virios Therapeutics (VIRI), Zhengye Biotechnology (ZYBT), Bright Minds Biosciences (DRUG), Molecular Partners (MOLN), Ocugen (OCGN), INmune Bio (INMB), Genfit (GNFT), Fulcrum Therapeutics (FULC), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Shattuck Labs vs. Contineum Therapeutics Virios Therapeutics Zhengye Biotechnology Bright Minds Biosciences Molecular Partners Ocugen INmune Bio Genfit Fulcrum Therapeutics Neoleukin Therapeutics Contineum Therapeutics (NASDAQ:CTNM) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation. Does the media refer more to CTNM or STTK? In the previous week, Shattuck Labs had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for Shattuck Labs and 3 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.64 beat Shattuck Labs' score of 0.37 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of CTNM or STTK? 58.7% of Shattuck Labs shares are owned by institutional investors. 10.5% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is CTNM or STTK more profitable? Contineum Therapeutics has a net margin of 0.00% compared to Shattuck Labs' net margin of -1,156.46%. Contineum Therapeutics' return on equity of -49.92% beat Shattuck Labs' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% Shattuck Labs -1,156.46%-61.92%-54.49% Do analysts prefer CTNM or STTK? Contineum Therapeutics currently has a consensus price target of $29.25, indicating a potential upside of 285.38%. Shattuck Labs has a consensus price target of $8.67, indicating a potential upside of 532.60%. Given Shattuck Labs' higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Shattuck Labs 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.40 Does the MarketBeat Community prefer CTNM or STTK? Shattuck Labs received 29 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 71.15% of users gave Shattuck Labs an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes8100.00% Underperform VotesNo VotesShattuck LabsOutperform Votes3771.15% Underperform Votes1528.85% Which has preferable valuation and earnings, CTNM or STTK? Contineum Therapeutics has higher revenue and earnings than Shattuck Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M3.91$22.72MN/AN/AShattuck Labs$6.44M10.16-$87.30M-$1.53-0.90 SummaryContineum Therapeutics beats Shattuck Labs on 9 of the 15 factors compared between the two stocks. Get Shattuck Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STTK vs. The Competition Export to ExcelMetricShattuck LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.40M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.906.1326.4618.82Price / Sales10.16309.83453.2580.30Price / CashN/A67.8344.0437.47Price / Book0.406.747.634.64Net Income-$87.30M$138.11M$3.18B$245.69M7 Day Performance3.01%-2.43%-1.91%-2.66%1 Month Performance22.32%-1.91%-0.19%-2.15%1 Year Performance-84.64%-5.03%16.70%12.90% Shattuck Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STTKShattuck Labs3.5411 of 5 stars$1.37+6.2%$8.67+532.6%-84.4%$65.40M$6.44M-0.90100News CoverageCTNMContineum Therapeutics2.9239 of 5 stars$8.25-1.9%$29.25+254.5%N/A$212.67M$50M0.0031News CoveragePositive NewsVIRIVirios TherapeuticsN/A$10.74-9.1%$3.00-72.1%+1,411.6%$206.83MN/A-39.785Gap DownZYBTZhengye BiotechnologyN/A$4.35+3.3%N/AN/A$205.19MN/A0.00N/AQuiet Period ExpirationGap DownDRUGBright Minds Biosciences4.1374 of 5 stars$46.29+5.3%$84.33+82.2%+1,829.8%$205.07MN/A-92.58N/AAnalyst ForecastAnalyst RevisionNews CoverageMOLNMolecular Partners0.135 of 5 stars$5.07+2.1%N/A+8.6%$204.79M$7.84M-2.36180News CoverageGap DownOCGNOcugen1.628 of 5 stars$0.70-1.7%$5.67+709.5%-35.8%$203.92M$6.04M-3.8980Positive NewsINMBINmune Bio2.3396 of 5 stars$9.12-5.0%$20.75+127.5%-31.8%$202.19M$160,000.00-4.1810Positive NewsGNFTGenfit1.2041 of 5 stars$3.92+0.3%$13.00+231.6%+4.0%$196M$41.31M0.00120FULCFulcrum Therapeutics1.8409 of 5 stars$3.63-1.6%$9.33+157.1%-59.6%$195.80M$2.81M-11.71100Upcoming EarningsNews CoverageNLTXNeoleukin TherapeuticsN/A$20.46-12.2%N/A-41.9%$192.28MN/A-6.5890News CoverageHigh Trading Volume Related Companies and Tools Related Companies Contineum Therapeutics Competitors Virios Therapeutics Competitors Zhengye Biotechnology Competitors Bright Minds Biosciences Competitors Molecular Partners Competitors Ocugen Competitors INmune Bio Competitors Genfit Competitors Fulcrum Therapeutics Competitors Neoleukin Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STTK) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STTK Stock Alerts